We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

177 hedge funds and large institutions have $944M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 67 increasing their positions, 53 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

26% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 53

8% more funds holding

Funds holding: 164177 (+13)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

3% less capital invested

Capital invested by funds: $972M → $944M (-$28.6M)

80% less call options, than puts

Call options by funds: $85K | Put options by funds: $434K

Holders
177
Holders Change
+13
Holders Change %
+7.93%
% of All Funds
2.55%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
27
Increased
67
Reduced
53
Closed
14
Calls
$85K
Puts
$434K
Net Calls
-$349K
Net Calls Change
-$898K
Name Holding Trade Value Shares
Change
Change in
Stake
UOC
51
UBS O'Connor
Illinois
$2.39M +$521K +33,876 +29%
Wellington Management Group
52
Wellington Management Group
Massachusetts
$2.37M +$1.57M +102,327 +211%
AG
53
Algert Global
California
$2.06M -$2.17M -141,044 -52%
Citadel Advisors
54
Citadel Advisors
Florida
$1.74M -$2.32M -150,738 -58%
CWM
55
CIBC World Markets
New York
$1.57M +$1.54M +100,000 New
SA
56
Sunesis Advisors
Kansas
$1.51M
BC
57
BIT Capital
Germany
$1.42M +$1.28M +83,178 +1,219%
Barclays
58
Barclays
United Kingdom
$1.39M -$1.18M -76,592 -46%
JAM
59
Jupiter Asset Management
United Kingdom
$1.38M
TI
60
Trexquant Investment
Connecticut
$1.37M -$750K -48,738 -36%
RhumbLine Advisers
61
RhumbLine Advisers
Massachusetts
$1.3M +$29.6K +1,923 +2%
Ameriprise
62
Ameriprise
Minnesota
$1.28M +$54.2K +3,523 +5%
PP
63
PDT Partners
New York
$1.12M -$1.05K -68 -0.1%
Swiss National Bank
64
Swiss National Bank
Switzerland
$1.12M +$20K +1,300 +2%
MAM
65
Martingale Asset Management
Massachusetts
$1.1M -$9.23K -600 -0.9%
Thrivent Financial for Lutherans
66
Thrivent Financial for Lutherans
Minnesota
$1.09M -$125K -8,145 -10%
VOYA Investment Management
67
VOYA Investment Management
Georgia
$1.07M -$54.2K -3,524 -5%
NRD
68
Nebula Research & Development
New York
$1.06M +$53.7K +3,486 +5%
Invesco
69
Invesco
Georgia
$1.03M +$681K +44,254 +208%
Fisher Asset Management
70
Fisher Asset Management
Washington
$981K
JP Morgan Chase
71
JP Morgan Chase
New York
$951K -$411K -26,695 -31%
AA
72
AlphaCentric Advisors
Puerto Rico
$944K +$923K +60,000 New
American Century Companies
73
American Century Companies
Missouri
$932K +$207K +13,440 +29%
Susquehanna International Group
74
Susquehanna International Group
Pennsylvania
$914K -$364K -23,617 -29%
AA
75
ALPS Advisors
Colorado
$896K +$112K +7,292 +15%

DCPH Hedge Fund Activity: Q1 2024 in Review

177 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q1 2024, worth a combined $944M — down 2.9% from $972M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new DCPH positions and 14 closed out — a net gain of 13 holders — while 67 added to existing stakes and 53 trimmed.

The largest buyer was Armistice Capital, adding an estimated $10.8M. The largest seller was Morgan Stanley, cutting an estimated $47.6M.

  • 177 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q1 2024, up from 164 in Q4 2023.
  • Funds reported $944M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q1 2024, down 2.9% quarter-over-quarter.
  • 27 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 14 closed out, a net change of +13 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Armistice Capital, an estimated $10.8M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was Morgan Stanley, an estimated $47.6M sold.

Based on aggregated 13F filings for Q1 2024.